A clinical study to evaluate the safety and efficacy of VISULAS Green Selective Laser Trabeculoplasty (SLT) in mild to moderate primary open angle glaucoma patients in Indian population. - Evaluation of VISULAS Green Selective Laser Trabeculoplasty (SLT) in Indian population

Carl Zeiss India Bangalore Pvt Ltd0 个研究点目标入组 0 人开始时间: 待定最近更新: 2023年5月1日

研究概览

暂无简介。

•1. Patients with mild to moderate primary open angle glaucoma who are eligible to undergo SLT treatment in one or both eyes
•2. IOP with or without medication >= 21 mmHg in the study eye
•3. Patients willing to give informed consent
•4. Patients are willing and able to return for follow-up examinations
•5.In the opinion of the investigator, the patient will be compliant and have a high probability of completing the data collection and all required procedures

•1. Very advanced glaucoma in either eye
•2. Congenital glaucoma
•3. Angle closure glaucoma, both primary and secondary
•4. Corneal disease or pathology in a way that distortion of laser light in the treated eye can be expected or that precludes stabilization of the cornea by the contact glass, visibility of the trabecular meshwork or transmission of laser wavelength
•5. Any known contraindication to SLT which include
•a. Angle closure glaucoma if trabecular meshwork is not visible
•b. Neovascular glaucoma
•c. Acute inflammatory glaucoma
•d. Blood vessels in the Schlemm canal
•6. Any kind of planned ocular surgeries during the next 3 months, for example, cataract surgery, in either eye
•7. History of intraocular surgery, ALT, or angle-based surgery
•8. Enrollment in another drug or device study within the prior 3 months

发起方

Carl Zeiss India Bangalore Pvt Ltd